IP Library Granted Patent US 8,921,102
Granted Patent B2
US 8,921,102 · App. 11/322,791 · Granted Dec 30, 2014

Devices and methods for enrichment and alteration of circulating tumor cells and other particles

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,921,102
App. No.
11/322,791
Granted
Dec 30, 2014
Kind
B2
Abstract

The invention features devices and methods for detecting, enriching, and analyzing circulating tumor cells and other particles. The invention further features methods of diagnosing a condition, e.g., cancer, in a subject by analyzing a cellular sample from the subject.

Claims (24)

1. A two-dimensional array of obstacles in a microfluidic device comprising:

a first subarray of obstacles comprising a first gap between at least two obstacles in said first subarray, wherein said first subarray comprises a plurality of rows of obstacles, wherein said obstacles of each successive row are offset by 50%; and

a second subarray of obstacles comprising a second gap between at least two obstacles in said second subarray, wherein said second subarray comprises a plurality of rows of obstacles, wherein said obstacles of each successive row of obstacles of said second subarray are offset by 50%,

and wherein said two-dimensional array comprises an interface between said first subarray and said second subarray, said interface comprising at least one restricted gap smaller than both said first gap and said second gap, wherein said obstacles of said first and second subarray protrude from a substrate and wherein said obstacles of said first subarray do not extend into said second subarray.

2. The array of claim 1 , wherein said substrate comprises plastic.

3. The array of claim 1 , wherein said array comprises a microfluidic gap.

4. The array of claim 1 , wherein said obstacles in said subarrays are staggered.

5. The array of claim 4 , further comprising a multiplicity of subarrays wherein said obstacles in adjacent subarrays are staggered periodically or uniformly.

6. The array of claim 1 , wherein each of said subarrays has between 6 and 20 obstacles.

7. The array of claim 1 , wherein said first gap is at least 40 microns.

8. The array of claim 1 , wherein a diameter of said obstacles is between 25 and 200 microns.

9. The array of claim 1 , wherein said restricted gap is less than 60 microns.

10. The array of claim 1 , wherein said array is coupled to one or more binding moieties that selectively bind one or more cells.

11. The array of claim 10 , wherein said one or more binding moieties comprise an antibody that selectively binds one or more epithelial cells, cancer cells, bone marrow cells, fetal cells, progenitor cells, stem cells, foam cells, mesenchymal cells, immune system cells, endothelial cells, endometrial cells, connective tissue cells, trophoblasts, bacteria, fungi, or pathogens.

12. The array of claim 1 , wherein said array is coupled to one or more binding moieties that selectively bind one or more cell surface cancer markers.

13. The array of claim 12 , wherein said one or more cell surface markers are selected from the group consisting of EpCAM, E-Cadherin, Mucin-1, Cytokeratin 8, EGFR, and leukocyte associated receptor (LAR).

14. The array of claim 1 , wherein said array of obstacles is coupled to a transparent cover.

15. The array of claim 1 wherein a spacing of said array is designed to encourage interaction of cells with said obstacles.

16. The array of claim 1 , wherein said second gap is at least 40 microns.

17. The array of claim 1 , wherein said restricted gap is at most 20 microns.

18. The array of claim 1 , wherein said first gap and said second gap are the same size.

19. The array of claim 1 , wherein said obstacles protrude approximately perpendicularly from said substrate.

20. The array of claim 1 , wherein said obstacles of said first subarray, said second subarray, or both are round.

21. The array of claim 1 , wherein said obstacles of said first and second subarray are substantially uniform in size.

Assignments (9)
CERTIFICATE OF CONVERSION FROM A LIMITED LIABILITY COMPANY TO A CORPORATION Recorded Jun 14, 2024
From: GPB SCIENTIFIC, LLC
To: GPB SCIENTIFIC, INC.
Reel/Frame 067737/0606 →
RELEASE OF SECURITY INTEREST Recorded Jun 14, 2024
From: SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY
To: GPB SCIENTIFIC, INC.
Reel/Frame 067732/0146 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2024
From: GPB SCIENTIFIC, INC. (D/B/A CURATE BIOSCIENCES)
To: CURATE (ABC), LLC
Reel/Frame 067737/0738 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2024
From: CURATE (ABC), LLC
To: ZEON CORPORATION
Reel/Frame 067737/0769 →
SECURITY INTEREST Recorded Sep 28, 2023
From: GPB SCIENTIFIC, INC.
To: FIRST-CITIZENS BANK & TRUST COMPANY
Reel/Frame 065082/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2016
From: ON-Q-ITY, INC.
To: GPB SCIENTIFIC, LLC
Reel/Frame 040581/0683 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2013
From: CELLECTIVE DX CORPORATION
To: GPB SCIENTIFIC, LLC
Reel/Frame 031007/0279 →
CHANGE OF NAME Recorded Sep 30, 2008
From: CELLPOINT DIAGNOSTICS, INC.
To: CELLECTIVE DX CORPORATION
Reel/Frame 021611/0738 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2006
From: FUCHS, MARTIN; WANG, YING-XIN; HUANG, YI-SHUIAN; KRUEGER, NEIL X.
To: CELLPOINT DIAGNOSTICS, INC.
Reel/Frame 018381/0042 →